About Caartigen
Caartigen was a Healthcare company based in India founded in 2019. It offers comprehensive stem cell and PRP treatments for orthopedic conditions. It operates on a B2B model. The company is recorded as dissolved. Its focus areas include Medical Treatments, Orthopedics and Stem Cell Therapy. Its legal entity in India is Sprygen Biotherapeutics Private Limited (U85100KA2020PTC131489).
Company details
Caartigen, established in 2019, excels in providing healthcare solutions, medical treatments, orthopedics, and stem cell therapy. Offers comprehensive stem cell and PRP treatments for orthopedic conditions. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
- Headquarters India
- SectorsHealthcare
- Website caartigen.com
- Legal Name Sprygen Biotherapeutics Private Limited
- Date of Incorporation 10 Jan, 2020
- Jurisdiction Bangalore, Karnataka, India
- Net Loss-₹11,900
FY 2024 · -11880% margin
Associated legal entities of Caartigen
Caartigen operates through Sprygen Biotherapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sprygen Biotherapeutics Private Limited CIN U85100KA2020PTC131489 | Active | 10 Jan 2020 | Bangalore, Karnataka | ₹0.0 Cr | 2 | View details |
Board of directors of Sprygen Biotherapeutics Private Limited (Caartigen)
Sprygen Biotherapeutics Private Limited is the primary company behind Caartigen. The board of Sprygen Biotherapeutics Private Limited currently have 2 directors; the longest-serving is Sujatha Shrinivas, appointed in 2020.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sujatha Shrinivas DIN 08554983 | Director | 10 Jan 2020 | 6 yrs 9 mo | Sprygen Biotherapeutics Private Limited |
| Natarajan Essakimuthu DIN 08618048 | Director | 10 Jan 2020 | 6 yrs 9 mo | Sprygen Biotherapeutics Private Limited |
Financials of Caartigen
Figures of Sprygen Biotherapeutics Private Limited, the primary company behind Caartigen, for FY 2024. Net loss was -₹11,900 (-11880% margin).
- -₹11,900Net loss · -11880% margin
- ₹1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Sprygen Biotherapeutics Private Limited are on its company page.
Detailed financial statements for Caartigen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Caartigen
Caartigen was founded in 2019.
Caartigen is headquartered in India.
Annual revenue of Caartigen is $1.17 as on Mar 31, 2024.
Caartigen, established in 2019, excels in providing healthcare solutions, medical treatments, orthopedics, and stem cell therapy. Offers comprehensive stem cell and PRP treatments for orthopedic conditions. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Caartigen operates through Sprygen Biotherapeutics Private Limited.
The legal entities of Caartigen currently have 2 directors, including Sujatha Shrinivas, Natarajan Essakimuthu.